615 related articles for article (PubMed ID: 32782249)
1. Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine.
Campesato LF; Budhu S; Tchaicha J; Weng CH; Gigoux M; Cohen IJ; Redmond D; Mangarin L; Pourpe S; Liu C; Zappasodi R; Zamarin D; Cavanaugh J; Castro AC; Manfredi MG; McGovern K; Merghoub T; Wolchok JD
Nat Commun; 2020 Aug; 11(1):4011. PubMed ID: 32782249
[TBL] [Abstract][Full Text] [Related]
2. Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan-Kynurenine-Aryl Hydrocarbon Axis.
Labadie BW; Bao R; Luke JJ
Clin Cancer Res; 2019 Mar; 25(5):1462-1471. PubMed ID: 30377198
[TBL] [Abstract][Full Text] [Related]
3. Blockade of IDO-Kynurenine-AhR Axis Ameliorated Colitis-Associated Colon Cancer via Inhibiting Immune Tolerance.
Zhang X; Liu X; Zhou W; Du Q; Yang M; Ding Y; Hu R
Cell Mol Gastroenterol Hepatol; 2021; 12(4):1179-1199. PubMed ID: 34087454
[TBL] [Abstract][Full Text] [Related]
4. Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO.
Kim M; Tomek P
Front Immunol; 2021; 12():636081. PubMed ID: 33708223
[TBL] [Abstract][Full Text] [Related]
5. Both IDO1 and TDO contribute to the malignancy of gliomas via the Kyn-AhR-AQP4 signaling pathway.
Du L; Xing Z; Tao B; Li T; Yang D; Li W; Zheng Y; Kuang C; Yang Q
Signal Transduct Target Ther; 2020 Feb; 5(1):10. PubMed ID: 32296044
[TBL] [Abstract][Full Text] [Related]
6. Kynurenine produced by indoleamine 2,3-dioxygenase 2 exacerbates acute liver injury by carbon tetrachloride in mice.
Hoshi M; Osawa Y; Nakamoto K; Morita N; Yamamoto Y; Ando T; Tashita C; Nabeshima T; Saito K
Toxicology; 2020 May; 438():152458. PubMed ID: 32289347
[TBL] [Abstract][Full Text] [Related]
7. IDO1/TDO dual inhibitor RY103 targets Kyn-AhR pathway and exhibits preclinical efficacy on pancreatic cancer.
Liang H; Li T; Fang X; Xing Z; Zhang S; Shi L; Li W; Guo L; Kuang C; Liu H; Yang Q
Cancer Lett; 2021 Dec; 522():32-43. PubMed ID: 34520819
[TBL] [Abstract][Full Text] [Related]
8. Role of tryptophan metabolism in cancers and therapeutic implications.
Liu XH; Zhai XY
Biochimie; 2021 Mar; 182():131-139. PubMed ID: 33460767
[TBL] [Abstract][Full Text] [Related]
9. Tryptophan depletion sensitizes the AHR pathway by increasing AHR expression and GCN2/LAT1-mediated kynurenine uptake, and potentiates induction of regulatory T lymphocytes.
Solvay M; Holfelder P; Klaessens S; Pilotte L; Stroobant V; Lamy J; Naulaerts S; Spillier Q; Frédérick R; De Plaen E; Sers C; Opitz CA; Van den Eynde BJ; Zhu J
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37344101
[TBL] [Abstract][Full Text] [Related]
10. Indoleamine 2,3-Dioxygenase Activity-Induced Acceleration of Tumor Growth, and Protein Kinases-Related Novel Therapeutics Regimens.
Engin AB; Engin A
Adv Exp Med Biol; 2021; 1275():339-356. PubMed ID: 33539022
[TBL] [Abstract][Full Text] [Related]
11. Interplay between Estrogen, Kynurenine, and AHR Pathways: An immunosuppressive axis with therapeutic potential for breast cancer treatment.
Pacheco JHL; Elizondo G
Biochem Pharmacol; 2023 Nov; 217():115804. PubMed ID: 37716620
[TBL] [Abstract][Full Text] [Related]
12. Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy.
Fujiwara Y; Kato S; Nesline MK; Conroy JM; DePietro P; Pabla S; Kurzrock R
Cancer Treat Rev; 2022 Nov; 110():102461. PubMed ID: 36058143
[TBL] [Abstract][Full Text] [Related]
13. Targeting the IDO1/TDO2-KYN-AhR Pathway for Cancer Immunotherapy - Challenges and Opportunities.
Cheong JE; Sun L
Trends Pharmacol Sci; 2018 Mar; 39(3):307-325. PubMed ID: 29254698
[TBL] [Abstract][Full Text] [Related]
14. Carboxyamidotriazole combined with IDO1-Kyn-AhR pathway inhibitors profoundly enhances cancer immunotherapy.
Shi J; Chen C; Ju R; Wang Q; Li J; Guo L; Ye C; Zhang D
J Immunother Cancer; 2019 Sep; 7(1):246. PubMed ID: 31511064
[TBL] [Abstract][Full Text] [Related]
15. Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism.
Nguyen NT; Kimura A; Nakahama T; Chinen I; Masuda K; Nohara K; Fujii-Kuriyama Y; Kishimoto T
Proc Natl Acad Sci U S A; 2010 Nov; 107(46):19961-6. PubMed ID: 21041655
[TBL] [Abstract][Full Text] [Related]
16. Increased kynurenine concentration attenuates serotonergic neurotoxicity induced by 3,4-methylenedioxymethamphetamine (MDMA) in rats through activation of aryl hydrocarbon receptor.
Abuin-Martínez C; Vidal R; Gutiérrez-López MD; Pérez-Hernández M; Giménez-Gómez P; Morales-Puerto N; O'Shea E; Colado MI
Neuropharmacology; 2021 Apr; 187():108490. PubMed ID: 33607146
[TBL] [Abstract][Full Text] [Related]
17. IDO1 Expression in Ovarian Cancer Induces PD-1 in T Cells
Amobi-McCloud A; Muthuswamy R; Battaglia S; Yu H; Liu T; Wang J; Putluri V; Singh PK; Qian F; Huang RY; Putluri N; Tsuji T; Lugade AA; Liu S; Odunsi K
Front Immunol; 2021; 12():678999. PubMed ID: 34025677
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cell-expressed IDO alleviates atherosclerosis by expanding CD4
Wang F; Liu M; Ma D; Cai Z; Liu L; Wang J; Zhang W; Zhao L; Zhai C; Xu Y
Int Immunopharmacol; 2023 Mar; 116():109758. PubMed ID: 36706593
[TBL] [Abstract][Full Text] [Related]
19. Indoleamine 2, 3-Dioxygenase Promotes Aryl Hydrocarbon Receptor-Dependent Differentiation Of Regulatory B Cells in Lung Cancer.
Tousif S; Wang Y; Jackson J; Hough KP; Strenkowski JG; Athar M; Thannickal VJ; McCusker RH; Ponnazhagan S; Deshane JS
Front Immunol; 2021; 12():747780. PubMed ID: 34867973
[TBL] [Abstract][Full Text] [Related]
20. Neuroendocrine tumours and their microenvironment.
de Hosson LD; Takkenkamp TJ; Kats-Ugurlu G; Bouma G; Bulthuis M; de Vries EGE; van Faassen M; Kema IP; Walenkamp AME
Cancer Immunol Immunother; 2020 Aug; 69(8):1449-1459. PubMed ID: 32270230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
